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ScienceDirectThe postsynaptic density (PSD) is a protein-rich assembly
below the postsynaptic membrane, formed of large scaffolding
proteins. These proteins carry a combination of protein
interaction domains, which may interact with several alternative
partners; the structure of the protein assembly can be regulated
in an activity-dependent manner. A major scaffolding molecule
in the PSD is Shank, a family of three main isoforms with highly
similar domain structure. Proteins of the Shank family are
targets of mutations in neurological disorders, such as autism
and schizophrenia. All the predicted folded domains of Shank
have now been crystallized. However, for an understanding of
the structure and function of full-length Shank and its
complexes in the supramolecular PSD assembly, novel
complementary approaches and hybrid techniques must be
employed.
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Thepostsynaptic density (PSD) is an electron-dense supra-
molecular structure made of specific proteins linking the
postsynaptic membrane to the neuronal cytoskeleton. The
PSD contains ‘scaffolding’ proteins, which have multiple
folded domains as well as regions predicted to be highly
flexible. PSD scaffold proteins belong to several protein
families, and they each carry distinct sets of protein inter-
action domains, which can be used not only to form multi-
valent contacts in the tight protein network of the PSD, but
also for regulating the PSD molecular assembly in an
activity-dependent manner. The latter is important for
the participation of the PSD in long-term potentiationCurrent Opinion in Structural Biology 2019, 54:122–128 and depression. The structure of the PSD varies between
excitatory and inhibitory synapses [1].
Different scaffold molecules are concentrated at different
depths of the PSD from the postsynaptic membrane [2,3].
The distribution of individual proteins can be regulated
by synaptic activity [4–7], which in turn may result in
changes in post-translational modifications as well as
interaction partners. While many interactions have been
well-characterized at the domain level, information is
lacking at the level of full-length scaffold proteins, con-
centrated into a dense phase at the PSD. Here, the
structures of the folded domains of the Shank scaffolding
proteins are reviewed, and aspects of full-length Shank
structure are considered.
Shank as a PSD scaffold protein
PSD scaffolding proteins belong to different families,
which differ in their modular domain composition.
Through these scaffolds, the postsynaptic membrane
and the receptors residing in it are linked to the cytoskel-
eton. The main PSD scaffolds include membrane-
associated guanylate kinases (such as PSD-95), Shanks,
calmodulin-dependent protein kinase II, Homer, synap-
tic Ras GTPase-activating protein 1, and guanylate
kinase-associated protein (GKAP) (Figure 1a). For many
of the individual domains in the scaffold proteins, struc-
tural data exist (see Table 1 for examples), but it is to a
large extent still unclear, how interactions and higher-
order assemblies form at the molecular level, and whether
and how different domains within the same large scaffold
protein might interact.
A central PSD scaffold is made up of proteins belonging
to the Shank family (Figure 1b). The three major isoforms
of Shank, produced from different genes, are highly
similar, and a molecular basis of their possible functional
differences is currently lacking. Mutations related
to neuropsychiatric or neurodevelopmental disorders,
including autism spectrum disorders and schizophrenia,
have been linked to the Shank proteins [8–13], but the
molecular effects of the mutations remain in general
unknown. Considering the nature of Shank as a large
molecule with several interaction partners, it is likely the
mutations will affect one or more of its molecular inter-
actions in a way that will disturb normal formation and
regulation of the PSD. Although the structural domain
components of Shank are rather simple in isolation, it is
the combination of them within the same polypeptide
chain that allows for multivalent interactions with otherwww.sciencedirect.com
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A Shank-centric view of the PSD assembly. (a) Simplified view of the
organization of the PSD. (b) The domain structure of full-length Shank
proteins.proteins in the PSD network and enables protein phase
separation to form the PSD assembly.
At the supramolecular level, Shank is known to both self-
assemble into large scaffolds as well as to form networks
with other PSD proteins [14,15]. Shank interaction part-
ners, including GKAP, are able to bind several protein
ligands, and regulatory proteins, such as Arc, may form
transient interactions in an activity-dependent manner
with different PSD proteins [16–18]. Different popula-
tions of Shank have been detected at different depths in
the PSD [3].Table 1
Structures of selected PSD scaffold protein domains. Note that for 
individual structures are referred to below
Scaffold protein Domains 
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While the Shank isoforms present themselves through
different splice isoforms [19], conserved domains are
readily identified. A conserved SPN (Shank/ProSAP N-
terminal) domain at the Shank N terminus has been
recognized, but only recent studies highlighted its func-
tional and structural details [20]. The SPN domain is
followed by ankyrin repeats. The central part of Shank
contains one copy each of the SH3 and PDZ domain —
classical protein interaction domains recognizing short
linear peptide motifs. The C terminus of Shank harbors
a SAM domain, shown to form a supramolecular lattice at
the PSD in a Zn-dependent manner [14].
While the SAM and PDZ domains have been structurally
characterized some years ago, data on the N-terminal
segment as well as the SH3 domain have now provided
crucial new information on the Shank family at the
molecular level (Figure 2). Recent research has high-
lighted a role for Shanks in integrin inactivation through
small GTP-binding proteins [20]. The N-terminal
domain of Shank is directly involved in these processes
through protein–protein interactions with Rap1 and R-
Ras. The SPN domain is structurally homologous to the
Rap1-binding domain in talin, which is a major regulator
of integrin activity. The ASD-linked mutations in the
SPN domain were shown to impair interactions with Rap1
[20], indicating possible disease mechanisms related to
protein interactions.
The Shank SH3 domain folds like a canonical SH3
domain (Figure 2b); however, the binding site for pro-
line-rich peptides, comprised of highly conserved aro-
matic residues in SH3 domains, has been lost in Shank
[21,22]. Accordingly, a large-scale screen for binding
motifs of human SH3 domains failed to find ligands for
any of the Shank SH3 domains [23]. Whether the SH3
domain could have specific ligands that do not conform to
the PxxP motif, has remained unclear until very recently.
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Crystal structures of all known folded domains of Shank. The sequence numbering for all domains corresponds to the rat Shank3 (UniProt
Q9JLU4), as nearly all structural data are from this protein. N and C termini are indicated by blue letters. (a) The SPN-ankyrin unit [20]. The SPN
domain folds back onto the ankyrin repeats. (b) The Shank3 SH3 domain [22]. Left: the high-resolution crystal structure [22], with the residues
mainly implicated in CaV1.3 peptide binding [21] in red. Right: Surface electrostatics indicate a highly polarized structure, with the CaV1.3 binding
site having a strong negative charge. The canonical loops and the peptide binding groove of SH3 domains are indicated. (c) The PDZ domain.
Left: The unliganded PDZ domain monomer [32]. Middle: Dimeric form of the PDZ domain [35]. Right: Another dimeric form induced by an
elongated GKAP peptide (magenta, arrow) [34]. (d) The Zn-bound SAM domain [14].been suggested [24,25], and an interaction between the
Shank ankyrin domain and the SH3 domain has been
reported, possibly linked to multimerization [26]. The
structures of the Shank SH3 domains were solved
by NMR, and a non-canonical direct interaction partner
was identified as the cytoplasmic domain of the
CaV1.3 channel [21]. This interaction is of electrostatic
nature (Figure 2b), and could play a role in linking
CaV1.3 channels to the PSD scaffold. CaV1.3 channels
are known to be important for neuronal function, and they
possibly play a role in PSD structure through interactions
with PDZ domains of the scaffold proteins [27]. It is
possible that the SH3 and PDZ domains both bind to the
cytoplasmic part of CaV1.3 [21]. In general, it is likely that
simultaneous interactions with two neighboring protein
interaction domains will increase the affinity of binding,
and the SH3-PDZ unit of Shank could be a functional
interaction module, providing a large interaction surface-
coupled to flexibility. Similarly, intramolecular interac-
tions between PDZ and SH3 domains were reported for
GKAP [28]. The finding of an unconventional SH3
domain that binds non-canonical ligands paves the way
for the identification of additional non-PxxP ligands for
SH3 domains, in which the aromatic binding site is not
conserved, including the SH3 domain of Caskin [29].
Caskins are members of a presynaptic protein scaffold,Current Opinion in Structural Biology 2019, 54:122–128 and similarly to Shank, in addition to a non-canonical SH3
domain, they contain SAM domains [30], which can
polymerize. The Caskin1 SH3 domain was shown to bind
lipids, such as lysophosphatidic acid, instead of proteins
[31]; such hypotheses are testable also in the case of
Shank.
The PDZ domain in Shanks binds to typical class I
ligands with high affinity [32]. In addition, recent screens
have identified internal binding motifs, which broaden
the ligand selection for the PDZ domain [33]. For known
Shank PDZ domain class I ligands, side-chain interac-
tions fine-tune the peptide affinity; the highest affinity
thus far has been detected toward the GKAP C terminus
[32]. In addition, an extended GKAP peptide ligand was
shown to interact with another binding site in the linker
between the SH3 and PDZ domains, resulting in an
order of magnitude higher affinity [34] — hence, for full
protein–protein complexes, affinities estimated through
binding assays involving a single domain and a short linear
peptide may provide misleading results in the biological
context.
Shank PDZ domain dimerization has been observed in
crystal structures both with and without bound ligand
peptides [34,35]. The two observed dimerization modeswww.sciencedirect.com
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(Figure 2c). Whether physiological binding partners cause
changes in full-length Shank oligomeric state and/or
conformation, such as seen in the crystal structures of
the extended PDZ domains, remains to be determined —
if this would be the case, it would provide truly novel
insights into the regulation of the PSD molecular
assembly.
The surface properties of the SH3 and PDZ domains may
give further clues to ligand interactions. Both domains are
electrostatically highly polarized [22,32], which may
promote their interactions with each other, as well as
with binding partners in the PSD. In addition, the SH3-
PDZ unit may have specific properties resulting from the
interplay of these domains connected by a linker, which is
less flexible than predicted and participates in ligand
protein binding [32,34]. It is likely that ligands binding
to a Shank PDZ domain through their C terminus in
addition have interactions with the SH3 domain and the
SH3-PDZ linker.
The C-terminal Shank SAM domain (Figure 2d) binds
zinc and is able to form homo-oligomeric structures [14].
Only the SAM domains of Shank2 and Shank3 bind
Zn, while Shank1 does not [36]. The SAM domain is
expected to form filaments/polymers, and the form used
for high-resolution structure determination was, indeed,
mutated to prevent this phenomenon [14]. Current
advances in cryo-EM data collection and processing
would be tempting approaches to solve a high-resolution
structure of this core assembly of the PSD.
From individual domains to full-length Shank
Considering full-length Shank, we must take into account
long regions predicted to be disordered. Between the
ankyrin repeats and the SH3 domain, a >100-residue
linker is present, which in a random coil conformation
would have an average length of 10 nm. The 40-residue
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Estimated dimensions of an extended full-length Shank molecule. Dimensio
[14,20,32], while those of the linkers have been calculated based on rando
www.sciencedirect.com be compact, and the SH3 and PDZ domains are close
together in solution [32]. The longest disordered region is
found between the PDZ and SAM domains, and its
length of 1000 residues would correspond to a random
chain of 30 nm in diameter. This proline-rich segment,
although not likely to be folded, is an important protein
interaction domain in Shank proteins. Taking into
account known structures, and the linkers between them,
one can estimate an average length of 60 nm for a single
Shank molecule (Figure 3). Multimerization of Shanks
via the SAM domain would, hence, generate huge assem-
blies of Shank, spanning large distances relative to the
size of the PSD. Until we obtain more structural data on
the linker regions and full-length Shank, we cannot be
sure of the conformation(s) Shank will sample in solution
and, more importantly, in the PSD. The median distance
of Shank, labelled with antibodies recognizing N-
terminal regions, from the postsynaptic membrane was
50 nm, with large variations, changes upon K+ or Ca2+
stimulation, and the presence of GKAP between Shank
and the membrane [3]. Considering the possible dimen-
sions of full-length Shank (Figure 3), it is possible that at
least some activity-dependent changes [4,6] could reflect
differences in Shank conformation and binding partners,
rather than complete relocalization of Shank, especially if,
for example, antibodies against one end of Shank are used
for localization studies.
Phase separation in the PSD is a recent suggestion for
the mechanism of formation of the PSD molecular
network [37]. Phase separation, or the formation of so-
called membraneless organelles, is an emerging theme in
many biological processes, and can be induced by prop-
erties of individual macromolecules and/or complexes
under specific conditions. The structural details of form-
ing a separated phase centered on Shank and other PSD
scaffolds still remain to be elucidated, although recent
work using various truncated PSD proteins has shed light
on the domains and interactions required for this phe-
nomenon [38].SAM
m
~30 nm 3 nm
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126 Proteins: 3D-structuresOverall, more information will be required to obtain an
accurate view on the structure and dynamics of full-
length Shank. Whether the various domains interact,
and if different segments of Shank – and its protein
complexes – form ‘supramodules’, such as those detected
in PSD-95 [39], are some of the questions that will require
the use of multidisciplinary and hybrid techniques. Cur-
rent technological advances in structural biology, micros-
copy, and biophysics may make solving the structure of
the PSD reality, and several practical aspects of this
process have been discussed [40].
Shank in disease
Scaffolding proteins of the PSD are putative targets for
mutations in neurological disorders [41]. In Shanks,
mutations have been linked to neurodevelop-
mental and neuropsychiatric disorders, such as ASD
[9,13,42,43]. Functional effects on protein interactions
were described for the mutations in the SPN domain
[20]. A number of mouse mutant models have been
used to decipher the in vivo roles of the Shank proteins in
the PSD. Common features include changes in the
molecular composition of the PSD and behavioral and
learning defects [44].
Can we use current structural data to understand the
possible molecular mechanisms of disease? Is it possible
to affect protein interactions in the PSD to treat such
disorders? The Shank family and its interactions with
other PSD proteins are considered to be promising targets
for pharmacological intervention, with the aim of affect-
ing neuropsychiatric disorders, such as ASD and schizo-
phrenia [43,44,45]. One important aspect hindering
these approaches is the lack of adequate high-resolution
structural information on both full-length Shank proteins
as well as the protein–protein complexes they form at the
PSD.
Conclusions
PSD is a highly complex molecular assembly, prone to
regulation by synaptic activity. In addition to the large,
multidomain scaffold proteins, the PSD contains regula-
tory elements, such as Arc, which interact with several
PSD scaffold proteins and may be linked to activity-
dependent changes of the synapse [16–18]. Methodolog-
ical developments in many fields will allow visualizing
PSD networks and events at the molecular level; such
approaches include, but are not limited to, high-through-
put proteomics, hybrid structural biology methods includ-
ing cryo-EM and tomography [46,47], super-resolution
microscopy coupled to specific nanobodies [48,49], as well
as biophysical techniques for following protein interac-
tions in vivo. The coming years will certainly bring about a
much improved view on the structure and function of
Shank and other PSD scaffold proteins.Current Opinion in Structural Biology 2019, 54:122–128 Funding
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